Progesterone receptor membrane component-1 regulates hepcidin biosynthesis

Journal of Clinical Investigation

Volumn 126, Issue 1, 2016, Pages 389-401

  Li, Xiang ^a,b   Rhee, David K ^a   Malhotra, Rajeev ^a   Mayeur, Claire ^a   Hurst, Liam A ^a   Ager, Emily ^a   Shelton, Georgia ^a   Kramer, Yael ^c   McCulloh, David ^c   Keefe, David ^c   Bloch, Kenneth D ^a   Bloch, Donald B ^a   Peterson, Randall T ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 6; CHORIONIC GONADOTROPIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; DEXAMETHASONE; EPITIOSTANOL; ESTROGEN; FERROPORTIN; HEPCIDIN; HEPCIDIN INDUCING STEROID; INTERLEUKIN 6; JANUS KINASE; MIFEPRISTONE; NEUTRALIZING ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE; PROGESTERONE RECEPTOR; PROGESTERONE RECEPTOR MEMBRANE COMPONENT 1; PROTEIN KINASE C; SMAD1 PROTEIN; STAT3 PROTEIN; STEROID; STEROID HORMONE; TESTOSTERONE; UNCLASSIFIED DRUG; WORTMANNIN; ANDROSTANE DERIVATIVE; CATION TRANSPORT PROTEIN; MEMBRANE PROTEIN; METAL TRANSPORTING PROTEIN 1; PGRMC1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; CELL CULTURE; CHEMICAL ANALYSIS; CLINICAL ASSESSMENT; CONTROLLED STUDY; FEMALE; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IRON METABOLISM; IRON OVERLOAD; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGESTERONE SYNTHESIS; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; ZEBRA FISH; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; HEP-G2 CELL LINE; PHYSIOLOGY;

ANDROSTANOLS; ANIMALS; BONE MORPHOGENETIC PROTEINS; CATION TRANSPORT PROTEINS; FEMALE; GENE EXPRESSION REGULATION; HEP G2 CELLS; HEPCIDINS; HUMANS; MEMBRANE PROTEINS; MICE; MIFEPRISTONE; PROGESTERONE; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; ZEBRAFISH;

EID: 84956666572     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI83831     Document Type: Article

References (64)

1. Zhao N, Zhang AS, Enns CA. Iron regulation by hepcidin. J Clin Invest. 2013;123(6):2337-2343.
2. Evstatiev R, Gasche C. Iron sensing and signalling. Gut. 2012;61(6):933-952.
3. Nemeth E, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090-2093.
4. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46(7):678-684.
5. Andriopoulos B Jr, et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet. 2009;41(4):482-487.
6. Babitt JL, et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet. 2006;38(5):531-539.
7. Meynard D, Kautz L, Darnaud V, Canonne-Hergaux F, Coppin H, Roth MP. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet. 2009;41(4):478-481.
8. Nemeth E, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113(9):1271-1276.
9. Verga Falzacappa MV, Vujic Spasic M, Kessler R, Stolte J, Hentze MW, Muckenthaler MU. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood. 2007;109(1):353-358.
10. Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood. 2006;108(9):3204-3209.
11. Pasricha SR, Frazer DM, Bowden DK, Anderson GJ. Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with β-thalassemia major: A longitudinal study. Blood. 2013;122(1):124-133.
12. Gardenghi S, et al. Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. Blood. 2007;109(11):5027-5035.
13. Adams PC, Barton JC. How I treat hemochromatosis. Blood. 2010;116(3):317-325.
14. Borgna-Pignatti C, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187-1193.
15. Neufeld EJ. Update on iron chelators in thalassemia. Hematology Am Soc Hematol Educ Program. 2010;2010:451-455.
16. Preza GC, et al. Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload. J Clin Invest. 2011;121(12):4880-4888.
17. Nai A, et al. Deletion of TMPRSS6 attenuates the phenotype in a mouse model of beta-thalassemia. Blood. 2012;119(21):5021-5029.
18. Ramos E, et al. Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. Blood. 2012;120(18):3829-3836.
19. Schmidt PJ, et al. An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia. Blood. 2013;121(7):1200-1208.
20. Korchynskyi O, ten Dijke P. Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter. J Biol Chem. 2002;277(7):4883-4891.
21. Casanovas G, Mleczko-Sanecka K, Altamura S, Hentze MW, Muckenthaler MU. Bone morphogenetic protein (BMP)-responsive elements located in the proximal and distal hepcidin promoter are critical for its response to HJV/BMP/ SMAD. J Mol Med (Berl). 2009;87(5):471-480.
22. Yu PB, et al. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol. 2008;4(1):33-41.
23. Zhang K, Chow PK. The effect of megestrol acetate on growth of HepG2 cells in vitro and in vivo. Clin Cancer Res. 2004;10(15):5226-5232.
24. Cahill MA. Progesterone receptor membrane component 1: an integrative review. J Steroid Biochem Mol Biol. 2007;105(1-5):16-36.
25. Rohe HJ, Ahmed IS, Twist KE, Craven RJ. PGRMC1 (progesterone receptor membrane component 1): A targetable protein with multiple functions in steroid signaling, P450 activation and drug binding. Pharmacol Ther. 2009;121(1):14-19.
26. Engmann L, Losel R, Wehling M, Peluso JJ. Progesterone regulation of human granulosa/ luteal cell viability by an RU486-independent mechanism. J Clin Endocrinol Metab. 2006;91(12):4962-4968.
27. Zhao X, et al. Interruption of cenph causes mitotic failure and embryonic death, and its haploinsufficiency suppresses cancer in zebrafish. J Biol Chem. 2010;285(36):27924-27934.
28. Swiatek-De Lange M, et al. Membrane-initiated effects of progesterone on calcium dependent signaling and activation of VEGF gene expression in retinal glial cells. Glia. 2007;55(10):1061-1073.
29. Zhang M, et al. Progesterone receptor membrane component 1 is a functional part of the glucagon-like peptide-1 (GLP-1) receptor complex in pancreatic beta cells. Mol Cell Proteomics. 2014;13(11):3049-3062.
30. Hanke JH, et al. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck-and FynT-dependent T cell activation. J Biol Chem. 1996;271(2):695-701.
31. Hou XY, Liu Y, Zhang GY. PP2, a potent inhibitor of Src family kinases, protects against hippocampal CA1 pyramidal cell death after transient global brain ischemia. Neurosci Lett. 2007;420(3):235-239.
32. Vandendriessche B, et al. The soluble guanylate cyclase activator BAY 58-2667 protects against morbidity and mortality in endotoxic shock by recoupling organ systems. PLoS One. 2013;8(8):e72155.
33. van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev. 2011;(10):CD009154.
34. Beggs LA, et al. Testosterone alters iron metabolism and stimulates red blood cell production independently of dihydrotestosterone. Am J Physiol Endocrinol Metab. 2014;307(5):E456-E461.
35. Casals-Pascual C, et al. Hepcidin demonstrates a biphasic association with anemia in acute Plasmodium falciparum malaria. Haematologica. 2012;97(11):1695-1698.
36. Dao MC, Sen S, Iyer C, Klebenov D, Meydani SN. Obesity during pregnancy and fetal iron status: is Hepcidin the link? J Perinatol. 2013;33(3):177-181.
37. Talbot NP, et al. Regulation of hepcidin expression at high altitude. Blood. 2012;119(3):857-860.
38. Steinbicker AU, et al. Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation. Blood. 2011;117(18):4915-4923.
39. Sun CC, Vaja V, Babitt JL, Lin HY. Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol. 2012;87(4):392-400.
40. Babitt JL, Huang FW, Xia Y, Sidis Y, Andrews NC, Lin HY. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest. 2007;117(7):1933-1939.
41. Meyer C, Schmid R, Scriba PC, Wehling M. Purification and partial sequencing of high-affinity progesterone-binding site(s) from porcine liver membranes. Eur J Biochem. 1996;239(3):726-731.
42. Min L, et al. Molecular identification of adrenal inner zone antigen as a heme-binding protein. FEBS J. 2005;272(22):5832-5843.
43. Peluso JJ, Pru JK. Non-canonical progesterone signaling in granulosa cell function. Reproduction. 2014;147(5):R169-R178.
44. Peluso JJ, Liu X, Saunders MM, Claffey KP, Phoenix K. Regulation of ovarian cancer cell viability and sensitivity to cisplatin by progesterone receptor membrane component-1. J Clin Endocrinol Metab. 2008;93(5):1592-1599.
45. Peluso JJ, Pappalardo A, Losel R, Wehling M. Progesterone membrane receptor component 1 expression in the immature rat ovary and its role in mediating progesterone's antiapoptotic action. Endocrinology. 2006;147(6):3133-3140.
46. Hughes AL, et al. Dap1/PGRMC1 binds and regulates cytochrome P450 enzymes. Cell Metab. 2007;5(2):143-149.
47. Mallory JC, et al. Dap1p, a heme-binding protein that regulates the cytochrome P450 protein Erg11p/Cyp51p in Saccharomyces cerevisiae. Mol Cell Biol. 2005;25(5):1669-1679.
48. Craven RJ, Mallory JC, Hand RA. Regulation of iron homeostasis mediated by the heme-binding protein Dap1 (damage resistance protein 1) via the P450 protein Erg11/Cyp51. J Biol Chem. 2007;282(50):36543-36551.
49. Peluso JJ, DeCerbo J, Lodde V. Evidence for a genomic mechanism of action for progesterone receptor membrane component-1. Steroids. 2012;77(10):1007-1012.
50. Meynard D, et al. Regulation of TMPRSS6 by BMP6 and iron in human cells and mice. Blood. 2011;118(3):747-756.
51. Hou Y, et al. Estrogen regulates iron homeostasis through governing hepatic hepcidin expression via an estrogen response element. Gene. 2012;511(2):398-403.
52. Ikeda Y, et al. Estrogen regulates hepcidin expression via GPR30-BMP6-dependent signaling in hepatocytes. PLoS One. 2012;7(7):e40465.
53. Yang Q, Jian J, Katz S, Abramson SB, Huang X. 17beta-Estradiol inhibits iron hormone hepcidin through an estrogen responsive element half-site. Endocrinology. 2012;153(7):3170-3178.
54. Guo W, et al. Testosterone administration inhibits hepcidin transcription and is associated with increased iron incorporation into red blood cells. Aging Cell. 2013;12(2):280-291.
55. Latour C, et al. Testosterone perturbs systemic iron balance through activation of epidermal growth factor receptor signaling in the liver and repression of hepcidin. Hepatology. 2014;59(2):683-694.
56. Kong WN, et al. Sex differences in iron status and hepcidin expression in rats. Biol Trace Elem Res. 2014;160(2):258-267.
57. Galesloot TE, et al. Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood. 2011;117(25):e218-e225.
58. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood. 2008;112(10):4292-4297.
59. Koenig MD, Tussing-Humphreys L, Day J, Cadwell B, Nemeth E. Hepcidin and iron homeostasis during pregnancy. Nutrients. 2014;6(8):3062-3083.
60. Apgar BS, Greenberg G. Using progestins in clinical practice. Am Fam Physician. 2000;62(8):1839-1846.
61. Fleseriu M, et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab. 2012;97(6):2039-2049.
62. Li X, Jia S, Wang S, Wang Y, Meng A. Mta3-NuRD complex is a master regulator for initiation of primitive hematopoiesis in vertebrate embryos. Blood. 2009;114(27):5464-5472.
63. Fraenkel PG, et al. Transferrin-A modulates hepcidin expression in zebrafish embryos. Blood. 2009;113(12):2843-2850.
64. Mayeur C, et al. The type I BMP receptor Alk3 is required for the induction of hepatic hepcidin gene expression by interleukin-6. Blood. 2014;123(14):2261-2268.